Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Post-marketing surveillance is crucial for evaluating long-term interferon beta-1a (IFNbeta-1a) therapy in multiple sclerosis (MS).
• Assessing safety, compliance, and clinical efficacy in a large patient cohort is essential.

Purpose of the Study:

• To evaluate the long-term safety, compliance, and clinical efficacy of intramuscular (i.m.) IFNbeta-1a in MS patients.
• To identify potential predictors of therapeutic response to i.m. IFNbeta-1a.

Main Methods:

• A cohort study including 255 MS patients receiving i.m. IFNbeta-1a.
• Data collected on treatment duration, discontinuation reasons, adverse events, Expanded Disability Status Scale (EDSS) scores, and relapse rates.
• Follow-up extended to 6.3 years.

Main Results:

• Mean therapy duration was 31.7 months; 31% discontinued treatment within 3 years, primarily due to disease activity.
• No significant sustained alterations in blood analysis were observed, except for decreased cholesterol levels.
• After 3 years, mean EDSS scores increased by 0.4, while the annual relapse rate decreased compared to baseline.
• Fewer relapses and lower baseline EDSS scores predicted longer time to relapse and progression.

Conclusions:

• Intramuscular IFNbeta-1a demonstrates a favorable safety profile and sustained effectiveness in MS patients over an extended follow-up period.
• The study suggests potential predictors for clinical outcomes, aiding in personalized treatment strategies.
• Long-term surveillance confirms the therapeutic value of i.m. IFNbeta-1a in managing multiple sclerosis.